Identification of RNA-binding protein hnRNP C targeting the 3’UTR of the TAP-associated glycoprotein tapasin in melanoma

References

• Su D, Kluger H, Olino K. Educational review: clinical application of immune checkpoint blockade for the treatment of melanoma. Ann Surg Oncol. 2023. doi:10.1245/s10434-023-14587-w. [ published Online First: 20231121].
   Web of Science ®Google Scholar
• Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320. doi:10.1038/s41392-023-01522-4. [ published Online First: 20230828].
   PubMed Web of Science ®Google Scholar
• Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023;43(43):e390614. doi:10.1200/EDBK_390614.
   PubMedGoogle Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535. [ published Online First: 20190503].
   PubMed Web of Science ®Google Scholar
• Jang A, Lichterman JN, Zhong JY, Shoag JE, Garcia JA, Zhang T, Barata PC. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. Hum Vaccin Immunother. 2023;19(3):2276629. doi:10.1080/21645515.2023.2276629. [ published Online First: 20231110].
   PubMed Web of Science ®Google Scholar
• Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194. doi:10.1186/s12943-023-01899-4. [ published Online First: 20231202].
   PubMed Web of Science ®Google Scholar
• Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. Immunol. 2019;158(4):255–11. doi:10.1111/imm.13114. [ published Online First: 20191001].
   PubMed Web of Science ®Google Scholar
• Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12:636568. doi:10.3389/fimmu.2021.636568. [ published Online First: 20210309].
   PubMed Web of Science ®Google Scholar
• Rene C, Lozano C, Eliaou JF. Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer award review 2015. HLA. 2016;87(5):338–349. doi:10.1111/tan.12787. [ published Online First: 20160406].
   PubMed Web of Science ®Google Scholar
• Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27(45):5869–5885. doi:10.1038/onc.2008.273.
   PubMed Web of Science ®Google Scholar
• Lazaridou MF, Gonschorek E, Massa C, Friedrich M, Handke D, Mueller A, Jasinski-Bergner S, Dummer R, Koelblinger P, Seliger B, et al. Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients. OncoImmunol. 2020;9(1):1774323. doi:10.1080/2162402X.2020.1774323.
   PubMed Web of Science ®Google Scholar
• Mari L, Hoefnagel SJM, Zito D, van de Meent M, van Endert P, Calpe S, Sancho Serra MDC, Heemskerk MHM, van Laarhoven HWM, Hulshof MCCM, et al. microRNA 125a regulates MHC-I expression on esophageal adenocarcinoma cells, associated with suppression of antitumor immune response and poor outcomes of patients. Gastroenterol. 2018;155(3):784–798. doi:10.1053/j.gastro.2018.06.030. [ published Online First: 20180607].
   PubMed Web of Science ®Google Scholar
• Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin Cancer Res. 2018;24(14):3366–3376. doi:10.1158/1078-0432.CCR-17-2483. [ published Online First: 20180301].
   PubMed Web of Science ®Google Scholar
• Lunde BM, Moore C, Varani G. RNA-binding proteins: modular design for efficient function. Nat Rev Mol Cell Biol. 2007;8(6):479–490. doi:10.1038/nrm2178.
   PubMed Web of Science ®Google Scholar
• Glisovic T, Bachorik JL, Yong J. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582(14):1977–1986. doi:10.1016/j.febslet.2008.03.004. [ published Online First: 20080313].
   PubMed Web of Science ®Google Scholar
• Ariyachet C, Solis NV, Liu Y, Prasadarao NV, Filler SG, McBride AE. SR-like RNA-binding protein Slr1 affects Candida albicans filamentation and virulence. Infect Immun. 2013;81(4):1267–1276. doi:10.1128/IAI.00864-12. [ published Online First: 20130204].
   PubMed Web of Science ®Google Scholar
• Brochu C, Cabrita MA, Melanson BD, Hamill JD, Lau R, Pratt MAC, McKay BC. NF-κB-dependent role for cold-inducible RNA binding protein in regulating interleukin 1β. PLOS ONE. 2013;8(2):e57426. doi:10.1371/journal.pone.0057426. [ published Online First: 20130221].
   PubMed Web of Science ®Google Scholar
• Wang ZL, Li B, Luo YX. Comprehensive genomic characterization of RNA-Binding proteins across human cancers. Cell Rep. 2018;22(1):286–298. doi:10.1016/j.celrep.2017.12.035.
   PubMed Web of Science ®Google Scholar
• Streitfeld WS, Dalton AC, Howley BV, Howe PH. PCBP1 regulates LIFR through FAM3C to maintain breast cancer stem cell self-renewal and invasiveness. Cancer Biol Ther. 2023;24(1):2271638. doi:10.1080/15384047.2023.2271638. [ published Online First: 20231106].
   PubMed Web of Science ®Google Scholar
• Jung M, Ji E, Kang H, Kim C, Ryu S, Han S, Cha S, Lee EK. The microRNA-195-5p/hnRNP A1 axis contributes to the progression of hepatocellular carcinoma by regulating the migration of cancer cells. Biochem Biophys Res Commun. 2023;686:149183. doi:10.1016/j.bbrc.2023.149183. [ published Online First: 20231030].
   PubMed Web of Science ®Google Scholar
• Lu Y, Bi T, Zhou S. MEX3A promotes angiogenesis in colorectal cancer via glycolysis. Libyan J Med. 2023;18(1):2202446. doi:10.1080/19932820.2023.2202446.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Ramsuran V, Rucevic M, Singh S, Lied A, Kulkarni V, O’hUigin C, Le Gall S, Carrington M. Posttranscriptional regulation of HLA-A protein expression by alternative polyadenylation signals involving the RNA-binding protein syncrip. J Immunol. 2017;199(11):3892–3899. doi:10.4049/jimmunol.1700697. [ published Online First: 20171020].
   PubMed Web of Science ®Google Scholar
• Reches A, Nachmani D, Berhani O, Duev-Cohen A, Shreibman D, Ophir Y, Seliger B, Mandelboim O. HNRNPR regulates the expression of classical and nonclassical MHC class I proteins. J Immunol. 2016;196(12):4967–4976. doi:10.4049/jimmunol.1501550. [ published Online First: 20160518].
   PubMed Web of Science ®Google Scholar
• van Hateren A, Elliott T. Visualising tapasin- and TAPBPR-assisted editing of major histocompatibility complex class-I immunopeptidomes. Curr Opin Immunol. 2023;83:102340. doi:10.1016/j.coi.2023.102340. [ published Online First: 20230526].
   PubMed Web of Science ®Google Scholar
• Muller IK, Winter C, Thomas C, Spaapen RM, Trowitzsch S, Tampé R. Structure of an MHC I–tapasin–ERp57 editing complex defines chaperone promiscuity. Nat Commun. 2022;13(1):5383. doi:10.1038/s41467-022-32841-9. [ published Online First: 20220914].
   PubMed Web of Science ®Google Scholar
• Boulanger DSM, Douglas LR, Duriez PJ, Kang Y, Dalchau N, James E, Elliott T. Tapasin-mediated editing of the MHC I immunopeptidome is epitope specific and dependent on peptide off-rate, abundance, and level of tapasin expression. Front Immunol. 2022;13:956603. doi:10.3389/fimmu.2022.956603. [ published Online First: 20221031].
   PubMed Web of Science ®Google Scholar
• Konig J, Zarnack K, Rot G, Curk T, Kayikci M, Zupan B, Turner DJ, Luscombe NM, Ule J. iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol. 2010;17(7):909–915. doi:10.1038/nsmb.1838. [ published Online First: 20100704].
   PubMed Web of Science ®Google Scholar
• Zheng J, Wu S, Tang M, Xi S, Wang Y, Ren J, Luo H, Hu P, Sun L, Du Y, et al. USP39 promotes hepatocellular carcinogenesis through regulating alternative splicing in cooperation with SRSF6/HNRNPC. Cell Death Dis. 2023;14(10):670. doi:10.1038/s41419-023-06210-3. [ published Online First: 20231011].
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xue X, Luo J, Li P, Xiao Z, Zhang W, Zhou J, Li P, Zhao J, Ge H, et al. Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA. Cancer Sci. 2023;114(9):3608–3622. doi:10.1111/cas.15899. [ published Online First: 20230707].
   PubMed Web of Science ®Google Scholar
• Cheng Y, Li L, Wei X, Xu F, Huang X, Qi F, Zhang Y, Li X. HNRNPC suppresses tumor immune microenvironment by activating treg cells promoting the progression of prostate cancer. Cancer Sci. 2023;114(5):1830–1845. doi:10.1111/cas.15745. [ published Online First: 20230213].
   PubMed Web of Science ®Google Scholar
• Cai Y, Lyu T, Li H, Liu C, Xie K, Xu L, Li W, Liu H, Zhu J, Lyu Y, et al. LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation via interacting with hnRNPC. J Exp Clin Cancer Res. 2022;41(1):335. doi:10.1186/s13046-022-02544-6. [ published Online First: 20221206].
   PubMed Web of Science ®Google Scholar
• He Q, Yang C, Xiang Z, Huang G, Wu H, Chen T, Dou R, Song J, Han L, Song T, et al. LINC00924-induced fatty acid metabolic reprogramming facilitates gastric cancer peritoneal metastasis via hnRNPC-regulated alternative splicing of Mnk2. Cell Death Dis. 2022;13(11):987. doi:10.1038/s41419-022-05436-x. [ published Online First: 20221123].
   PubMed Web of Science ®Google Scholar
• Liu D, Luo X, Xie M, Zhang T, Chen X, Zhang B, Sun M, Wang Y, Feng Y, Ji X, et al. HNRNPC downregulation inhibits IL-6/STAT3-mediated HCC metastasis by decreasing HIF1A expression. Cancer Sci. 2022;113(10):3347–3361. doi:10.1111/cas.15494. [ published Online First: 20220812].
   PubMed Web of Science ®Google Scholar
• Pan C, Wu Q, Feng N. A systematic pan-cancer study demonstrates the oncogenic function of heterogeneous nuclear ribonucleoprotein C. Aging (Albany NY). 2022;14(6):2880–2901. doi:10.18632/aging.203981. [ published Online First: 20220328].
   PubMedGoogle Scholar
• Cholewa BD, Pellitteri-Hahn MC, Scarlett CO, Ahmad N. Large-scale label-free comparative proteomics analysis of polo-like Kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF V600E mutant melanoma cells. J Proteome Res. 2014;13(11):5041–5050. doi:10.1021/pr5002516. [ published Online First: 20140609].
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Seol HJ, Park YM, Kim KH, Gorospe M, Nam DH, Kim HH. MicroRNA-146a suppresses metastatic activity in brain metastasis. Molecules And Cells. 2012;34(3):329–334. doi:10.1007/s10059-012-0171-6. [ published Online First: 20120903].
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273. doi:10.1038/ng1180.
   PubMed Web of Science ®Google Scholar
• Hazini A, Fisher K, Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021;9(8):e002899. doi:10.1136/jitc-2021-002899.
   PubMed Web of Science ®Google Scholar
• Matsuda-Lennikov M, Ohigashi I, Takahama Y. Tissue-specific proteasomes in generation of MHC class I peptides and CD8+ T cells. Curr Opin Immunol. 2022;77:102217. doi:10.1016/j.coi.2022.102217. [ published Online First: 20220608].
   PubMed Web of Science ®Google Scholar
• Mani R, Abdelaziz MH, Michelon A, Suzuki Y. Human MHC class I molecule, HLA-A2.1, mediates activation of CD8+ T cell IFN-γ production and the T cell-dependent protection against reactivation of cerebral toxoplasma infection. Front Immunol. 2022;13:1005059. doi:10.3389/fimmu.2022.1005059. [ published Online First: 20221013].
   PubMed Web of Science ®Google Scholar
• Perea F, Sanchez-Palencia A, Gomez-Morales M, Bernal M, Concha Á, García MM, González-Ramírez AR, Kerick M, Martin J, Garrido F, et al. HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget. 2018;9(3):4120–4133. doi:10.18632/oncotarget.23469. [ published Online First: 20171219].
   PubMedGoogle Scholar
• Han SH, Kim M, Chung YR, Woo JW, Choi HY, Park SY. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer. Sci Rep. 2022;12(1):20367. doi:10.1038/s41598-022-24890-3. [ published Online First: 20221127].
   PubMedGoogle Scholar
• Wang Y, Jasinski-Bergner S, Wickenhauser C, Seliger B. Cancer immunology: immune escape of tumors—expression and regulation of HLA class I molecules and its role in immunotherapies. Advan Anatom Pathol. 2023;30(3):148–159. doi:10.1097/PAP.0000000000000389. [ published Online First: 20221215].
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhao W, Liu Y, Tan X, Li X, Zou Q, Xiao Z, Xu H, Wang Y, Yang X, et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response. Embo J. 2018;37(23). doi:10.15252/embj.201899017. [ published Online First: 20180829].
   Web of Science ®Google Scholar
• Shi S, Wu T, Ma Z, Zhang X, Xu K, Tian Q, Gao L, Yin X, Xu S, Yang S, et al. Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5. J Cancer Res Clin Oncol. 2023;149(8):4639–4651. doi:10.1007/s00432-022-04375-6. [ published Online First: 20220929].
   PubMed Web of Science ®Google Scholar
• Bao Y, Qiao Y, Choi JE, Zhang Y, Mannan R, Cheng C, He T, Zheng Y, Yu J, Gondal M, et al. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy. Proc Natl Acad Sci USA. 2023;120(49):e2314416120. doi:10.1073/pnas.2314416120. [ published Online First: 20231127].
   PubMed Web of Science ®Google Scholar
• Lazaridou MF, Massa C, Handke D, Mueller A, Friedrich M, Subbarayan K, Tretbar S, Dummer R, Koelblinger P, Seliger B, et al. Identification of microRNAs targeting the transporter associated with antigen processing TAP1 in melanoma. J Clin Med. 2020;9(9):2690. doi:10.3390/jcm9092690. [ published Online First: 20200820].
   PubMed Web of Science ®Google Scholar
• Friedrich M, Vaxevanis CK, Biehl K, Mueller A, Seliger B. Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744. J Immunother Cancer. 2020;8(1):e000396. doi:10.1136/jitc-2019-000396.
   PubMed Web of Science ®Google Scholar
• Matsui M, Kawano M, Matsushita S. Introduction of a point mutation into an HLA class I single-chain trimer induces enhancement of CTL priming and antitumor immunity. Mol Ther Methods Clin Dev. 2014;1:14027. doi:10.1038/mtm.2014.27. [ published Online First: 20140702].
   PubMed Web of Science ®Google Scholar
• Jongsma MLM, Guarda G, Spaapen RM. The regulatory network behind MHC class I expression. Mol Immunol. 2019;113:16–21. doi:10.1016/j.molimm.2017.12.005. [ published Online First: 20171208].
   PubMed Web of Science ®Google Scholar
• Wu Z, Zuo X, Zhang W, Li Y, Gui R, Leng J, Shen H, Pan B, Fan L, Li J, et al. m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia. Adv Sci. 2023;10(34):e2304895. doi:10.1002/advs.202304895. [ published Online First: 20231011].
   Web of Science ®Google Scholar
• Gu Z, Yang Y, Ma Q, Wang H, Zhao S, Qi Y, Li Y. HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells. Respir Res. 2022;23(1):362. doi:10.1186/s12931-022-02227-y. [ published Online First: 20221219].
   PubMed Web of Science ®Google Scholar
• Xia N, Yang N, Shan Q. HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer. J Cell Mol Med. 2022;26(8):2322–2336. doi:10.1111/jcmm.17254. [ published Online First: 20220311].
   PubMed Web of Science ®Google Scholar
• Huang GZ, Wu QQ, Zheng ZN, Shao TR, Chen YC, Zeng WS, Lv XZ. M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT. Aging (Albany NY). 2020;12(12):11667–11684. doi:10.18632/aging.103333. [ published Online First: 20200611].
   PubMedGoogle Scholar
• Wang Y, Lazaridou MF, Massa C. 910 Overexpression of miR-155–5p can upregulate antigen processing and presentation pathway via targeting tapasin. J Immunother Cancer. 2021;9(Suppl 2):A956–A56. doi:10.1136/jitc-2021-SITC2021.910.
   Google Scholar
• Kattan FG, Koukouraki P, Anagnostopoulos AK, Tsangaris GT, Doxakis E. RNA binding protein AUF1/HNRNPD regulates nuclear export, stability and translation of SNCA transcripts. Open Biol. 2023;13(11):230158. doi:10.1098/rsob.230158. [ published Online First: 20231122].
   PubMed Web of Science ®Google Scholar
• Chen Z, Pi H, Zheng W, Guo X, Shi C, Wang Z, Zhang J, Qu X, Liu L, Shen H, et al. The 3′ non-coding sequence negatively regulates PD-L1 expression, and its regulators are systematically identified in pan-cancer. Genes (Basel). 2023;14(8):1620. doi:10.3390/genes14081620. [ published Online First: 20230813].
   PubMed Web of Science ®Google Scholar
• Yang YC, Lin YW, Lee WJ, Lai FR, Ho KH, Chu CY, Hua KT, Chen JQ, Tung MC, Hsiao M, et al. The RNA-binding protein KSRP aggravates malignant progression of clear cell renal cell carcinoma through transcriptional inhibition and post-transcriptional destabilization of the NEDD4L ubiquitin ligase. J Biomed Sci. 2023;30(1):68. doi:10.1186/s12929-023-00949-9. [ published Online First: 20230814].
   PubMed Web of Science ®Google Scholar
• Wu P. Inhibition of RNA-binding proteins with small molecules. Nat Rev Chem. 2020;4(9):441–458. doi:10.1038/s41570-020-0201-4. [ published Online First: 20200715].
   PubMed Web of Science ®Google Scholar